Is Buying MEDICINE MAN TECH INCORPORATED (OTCMKTS:MDCL), Having Higher Short Interest a Winning Strategy?

February 15, 2018 - By Kurt Siggers

The stock of MEDICINE MAN TECH INCORPORATED (OTCMKTS:MDCL) registered an increase of 2.75% in short interest. MDCL’s total short interest was 41,100 shares in February as published by FINRA. Its up 2.75% from 40,000 shares, reported previously. With 75,500 shares average volume, it will take short sellers 1 days to cover their MDCL’s short positions.

The stock increased 1.89% or $0.05 during the last trading session, reaching $2.7. About 5,099 shares traded. Medicine Man Technologies, Inc. (OTCMKTS:MDCL) has 0.00% since February 15, 2017 and is . It has underperformed by 16.70% the S&P500.

Medicine Man Technologies, Inc. provides cultivation consulting services for cannabis growing technologies and methodologies. The company has market cap of $59.06 million. The firm also provides licensing and seminar services. It currently has negative earnings. In addition, it engages in retail activities of cannabis products.

More notable recent Medicine Man Technologies, Inc. (OTCMKTS:MDCL) news were published by: Globenewswire.com which released: “Medicine Man Technologies Reports Third Quarter 2017 Results” on November 13, 2017, also Globenewswire.com with their article: “Medicine Man Technologies Secures a German Tender Client and Establishes a …” published on October 18, 2017, Globenewswire.com published: “Medicine Man Technologies to Launch its ‘Three a Light’ ® Mobile App” on January 24, 2018. More interesting news about Medicine Man Technologies, Inc. (OTCMKTS:MDCL) were released by: Globenewswire.com and their article: “Medicine Man Technologies Reports Second Quarter 2017 Results” published on August 17, 2017 as well as Globenewswire.com‘s news article titled: “Medicine Man Technologies Inc. to Acquire Denver Consulting Group” with publication date: May 09, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.